The review article discusses the options to extend anticoagulant therapy after completing the main anticoagulant therapy course in patients. who survived pulmonary embolism. It presents the results of randomized RE-MEDY and RE-SONATE studies of dabigatran. EINSTEIN-Extension study of rivaroxaban and AMPLIFY-Extension study of apixaban. https://www.diegojavierfares.com/quick-save-Omni-Logic-Plus-450g-great-price/